Advisory board

The Oxford Antibiotic Group has established a comprehensive network of advisors to support and challenge the company’s drug development strategy.

The Advisory Board is chaired by Prof. Dr. Mark Moloney, University of Oxford, and comprises a number of international experts in the field of antibacterial drug development.


Prof. Dr. Mark Moloney (University of Oxford – Dept. of Chemistry)

Mark is a renowned scientist and academic and has been participating in natural product chemistry research at the University of Oxford for more than 30 years. In his role at Oxford, Mark has collaborated extensively with industry, in particular, the pharmaceutical industry, and has founded Oxford Advanced Surfaces, a university spin out company in the area of polymer surface chemistry. He is one of the initiators of Oxford Antibiotic Group and leads the Oxford based research for the company. 

As synthetic organic chemist by training, Mark’s broad spectrum of expertise includes natural products and materials chemistry. Mark was a founding member of the charity, Antibiotic Research UK, has published more than 200 publications in high ranking journals and has written four undergraduate textbooks.


Prof. Dr. Martin Czejka (University of Vienna – Pharmacology)

Martin is a pharmacologist by training and vice-head of the Department for Clinical Pharmacy and Diagnostics at the University of Vienna. Martin has more than 30 years of experience working in drug development and specializes in ADME pharmacokinetics and pharmacogenetics of drugs. He has previously served on the board of other antibiotic companies and is the President of the Austrian Society of Applied Pharmacokinetics.


Prof. Dr. Heinz Burgmann (Medical University Vienna)

Heinz is one of the top scientists of the Division of Infectious Diseases at the Medical University of Vienna and is Austria’s leading expert for drug resistant microbes. With his research activities and his involvement in several clinical studies, he has gained a comprehensive knowledge in pre-clinical and clinical development. Heinz holds a degree in human medicine from the University of Vienna and has authored more than 100 publications in the field of anti-infective substances.


Indraneil Mahapatra, MSc. MBA (Kingsley Capital, London)

Neil began his career at Morgan Stanley in London and before founding Kingsley worked at J. Rothschild Capital Management, leading several illiquid transactions for Lord Rothschild’s family office and RIT Capital Partners plc. Neil sources and manages a variety of illiquid investments for KCP. He is a Director of portfolio company Forma Holdings and Oxford Cannabinoid Technologies, a member of the investment committee at Albright Capital Management, and a board member of emerging markets design firm MASS Group. He holds a degree in Biological Sciences from the University of Oxford and an MBA from the Harvard Business School.